Stockscreener 앱 받기
2.30
10.16%
-0.26
시간 외 거래:
2.41
0.11
+4.78%
전일 마감가:
$2.56
열려 있는:
$2.55
하루 거래량:
217.78K
Relative Volume:
0.69
시가총액:
$56.80M
수익:
$23.26M
순이익/손실:
$-63.41M
주가수익비율:
-0.9746
EPS:
-2.36
순현금흐름:
$-64.56M
1주 성능:
-15.44%
1개월 성능:
-16.06%
6개월 성능:
+32.18%
1년 성능:
+19.79%
1일 변동 폭
$2.25
$2.56
1주일 범위
$2.25
$2.72
52주 변동 폭
$1.21
$3.812
Aadi Bioscience Inc Stock (AADI) Company Profile
명칭
Aadi Bioscience Inc
전화
424-473-8055
주소
17383 SUNSET AVENUE, PACIFIC PALISADES
AADI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
2.30 | 56.80M | 23.26M | -63.41M | -64.56M | -2.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Aadi Bioscience Inc 주식(AADI)의 최신 뉴스
Aadi Bioscience CFO sells $6,594 in shares - Investing.com India
Aadi Bioscience CEO Lennon sells $13,371 in stock - Investing.com India
Aadi Bioscience CEO Sells Shares to Cover Tax Obligations - TradingView
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - PR Newswire
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy - MSN
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference -February 24, 2025 at 08:01 am EST - Marketscreener.com
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference - GuruFocus.com
Aadi Bioscience cut to hold at Jefferies following Fyarro failure in solid tumors - MSN
3 US Penny Stocks With Market Caps Over $30M To Watch - Yahoo Finance
Aadi Bioscience names new CSO to advance ADC pipeline - Investing.com India
Aadi Bioscience names new CSO to advance ADC pipeline By Investing.com - Investing.com South Africa
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - Quantisnow
Peapod Lane Capital LLC Makes New $1.40 Million Investment in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Growth in Short Interest - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - Defense World
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Declines By 13.7% - MarketBeat
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 - Quantisnow
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Decrease in Short Interest - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Growth in Short Interest - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Increase in Short Interest - Defense World
ACUTA CAPITAL PARTNERS, LLC Expands Stake in Aadi Bioscience Inc - GuruFocus.com
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Lowered by Jane Street Group LLC - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Shares Sold by Jane Street Group LLC - MarketBeat
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Rises By 136.0% - Defense World
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Grows By 136.0% - MarketBeat
Aadi Bioscience (NASDAQ:AADI) Shares Down 16.1% – What’s Next? - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 16.1%What's Next? - MarketBeat
Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World
Aadi Bioscience, Inc. announced that it expects to receive $100.002392 million in funding from a group of investors - Marketscreener.com
Aadi Bioscience Sale of FYARRO® to Kaken Pharmaceutical and In-Licensing of Novel ADC Portfolio from WuXi Biologics - Leerink Partners
Aadi Bioscience Leads 3 Promising US Penny Stocks - Simply Wall St
Aadi Bioscience rockets 72% on key updates - MSN
Aadi Bioscience’s Strategic Agreements and Funding Moves - Yahoo Finance
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Citeline
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga
Aadi Bioscience stock soars on licensing and sale deals - Investing.com India
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance
Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com
Clinical Trials News Live Feed - StockTitan
Aadi Bioscience Inc (AADI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.13%
1.23%
자본화:
|
볼륨(24시간):